stimulator of chondrogenesis 1Genealiases: SCRG-1 · lincSCRG1
Q-omics provides the consensus-scored SCRG1 profile across patient tissues and cancer cell-line models. SCRG1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SCRG1 is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, SCRG1 RNA expression shows 17,412 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight UVM, KICH, and PDAC as cancer lineages where SCRG1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SCRG1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SCRG1 survival associations across molecular data types. SCRG1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SCRG1 RNA expression–survival associations across cancer types. High SCRG1 expression shows unfavorable associations in UVM, KIRP, BLCA, OV and THYM, but favorable associations in DLBC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for SCRG1 RNA expression.
This table summarizes SCRG1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for SCRG1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SCRG1 shows lower tumor expression in KICH, BLCA, COAD, THCA, LUSC and UCEC. The KICH box plot shows higher SCRG1 RNA expression in normal versus tumor tissue (log2 FC = −0.521, t-test p < 0.001).
This table shows molecular features associated with SCRG1 in patient tissues and cancer cell lines. In patient samples, SCRG1 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, SCRG1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and SKIN.
